Kapur Anil 4
4 · Nurix Therapeutics, Inc. · Filed May 15, 2026
Research Summary
AI-generated summary of this filing
Nurix (NRIX) Director Anil Kapur Receives 31,250-Share Award
What Happened
Anil Kapur, a director of Nurix Therapeutics, received a derivative equity award for 31,250 shares on 2026-05-15. The filing lists the acquisition price as $0.00 (reporting code A — grant/award). This is an equity award that does not represent an immediate open-market purchase or sale by the insider.
Key Details
- Transaction date: 2026-05-15 (reported same day).
- Amount: 31,250 shares recorded as a derivative award; price reported $0.00.
- Shares owned after transaction: Not disclosed in this Form 4.
- Vesting/conditions: Footnote states the award vests 100% on the earlier of the next annual stockholder meeting or May 15, 2027, subject to Kapur’s continued service on the vesting date.
- Filing timeliness: Reported on the filing date (no late filing indicated).
Context
This is a grant/award (derivative) rather than a market purchase or sale. The award appears subject to time-based vesting and does not indicate any immediate sale or cashless exercise; until vesting, the economic or voting rights may be limited. Such grants are common for directors as compensation and are not a direct buy/sell signal of short-term market views.
Insider Transaction Report
- Award
Director Stock Option (right to buy)
[F1]2026-05-15+31,250→ 31,250 totalExercise: $15.86Exp: 2036-05-14→ Common Stock (31,250 underlying)
Footnotes (1)
- [F1]The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.